Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-14 8:26 pm Purchase |
2025-05-08 | 13G | Rein Therapeutics Inc. RNTX |
Voss Value Master Fund, LP | 1,277,856 5.600% |
1,277,856 (New Position) |
Filing History |
| 2024-11-05 5:17 pm Sale |
2024-11-04 | 13G | Rein Therapeutics Inc. RNTX |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 960,665 4.400% |
-851,962 (-47.00%) |
Filing History |
| 2024-04-16 5:16 pm Sale |
2024-04-02 | 13D | Rein Therapeutics Inc. RNTX |
Satter Muneer A | 830,466 4.900% |
-186,567 (-18.34%) |
Filing History |
| 2024-03-05 7:14 pm Purchase |
2024-02-28 | 13G | Rein Therapeutics Inc. RNTX |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 1,812,627 6.200% |
1,812,627 (New Position) |
Filing History |
| 2024-03-05 4:30 pm Purchase |
2024-03-05 | 13D | Rein Therapeutics Inc. RNTX |
Satter Muneer A | 1,017,033 5.900% |
9,545 (+0.95%) |
Filing History |
| 2024-02-14 10:28 am Sale |
2023-12-31 | 13G | Rein Therapeutics Inc. RNTX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-236,835 (Position Closed) |
Filing History |
| 2024-02-05 1:20 pm Unchanged |
2023-12-31 | 13G | Rein Therapeutics Inc. RNTX |
Scott Kapnick | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2023-11-13 5:08 pm Purchase |
2023-10-31 | 13G | Rein Therapeutics Inc. RNTX |
BIOS Fund I LP | 542,256 9.990% |
542,256 (New Position) |
Filing History |
| 2023-11-03 4:30 pm Purchase |
2023-10-31 | 13D | Rein Therapeutics Inc. RNTX |
Satter Muneer A | 1,007,488 19.900% |
1,007,488 (New Position) |
Filing History |
| 2023-02-14 11:42 am Purchase |
2022-12-31 | 13G | Rein Therapeutics Inc. RNTX |
BIOTECHNOLOGY VALUE FUND L P | 236,835 5.200% |
236,835 (New Position) |
Filing History |
| 2023-02-14 07:54 am Sale |
2022-12-31 | 13G | Aileron Therapeutics, Inc. ALRN |
Scott Kapnick | 379,608 8.400% |
-3 (-0.00%) |
Filing History |
| 2022-02-14 09:02 am Purchase |
2021-12-31 | 13G | Aileron Therapeutics, Inc. ALRN |
Scott Kapnick | 18,981 8.400% |
10,538 (+124.81%) |
Filing History |
| 2021-02-10 09:53 am Unchanged |
2020-12-31 | 13G | Aileron Therapeutics, Inc. ALRN |
Jennison Associates LLC | 3,856 3.700% |
0 (Unchanged) |
Filing History |
| 2021-02-09 12:39 pm Unchanged |
2021-02-05 | 13G | Aileron Therapeutics, Inc. ALRN |
PRUDENTIAL FINANCIAL INC PRU |
3,856 3.650% |
0 (Unchanged) |
Filing History |
| 2021-01-19 5:21 pm Purchase |
2021-01-06 | 13G | Aileron Therapeutics, Inc. ALRN |
BIOTECHNOLOGY VALUE FUND L P | 13,164 6.300% |
13,164 (New Position) |
Filing History |
| 2021-01-08 4:04 pm Purchase |
2021-01-06 | 13D | Aileron Therapeutics, Inc. ALRN |
Satter Muneer A | 50,852 19.900% |
22,500 (+79.36%) |
Filing History |